Nandrolone cyclohexanecarboxylate
Tools
Actions
General
Print/export
In other projects
Appearance
From Wikipedia, the free encyclopedia
Synthetic androgen and anabolic steroid
Clinical data | |
---|---|
Trade names | Nor-Durandron, Norlongandron |
Other names | NSC-3351; Nandrolone hexahydrobenzoate; 19-Nortestosterone 17β-cyclohexanecarboxylate |
Routes of administration | Intramuscular injection |
Drug class | Androgen; Anabolic steroid; Androgen ester; Progestogen |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C25H36O3 |
Molar mass | 384.560 g·mol−1 |
3D model (JSmol) | |
| |
|
Nandrolone cyclohexanecarboxylate (brand names Nor-Durandron, Norlongandron; former developmental code name NSC-3351), or nandrolone hexahydrobenzoate, also known as 19-nortestosterone 17β-cyclohexanecarboxylate, is a synthetic androgen and anabolic steroid and a nandrolone ester that has been marketed by Ferring Pharmaceuticals since at least 1961.[1][2][3][4][5]
Compound | PRTooltip Progesterone receptor | ARTooltip Androgen receptor | ERTooltip Estrogen receptor | GRTooltip Glucocorticoid receptor | MRTooltip Mineralocorticoid receptor | SHBGTooltip Sex hormone-binding globulin | CBGTooltip Corticosteroid-binding globulin |
---|---|---|---|---|---|---|---|
Nandrolone | 20 | 154–155 | <0.1 | 0.5 | 1.6 | 1–16 | 0.1 |
Testosterone | 1.0–1.2 | 100 | <0.1 | 0.17 | 0.9 | 19–82 | 3–8 |
Estradiol | 2.6 | 7.9 | 100 | 0.6 | 0.13 | 8.7–12 | <0.1 |
Notes: Values are percentages (%). Reference ligands (100%) were progesterone for the PRTooltip progesterone receptor, testosterone for the ARTooltip androgen receptor, estradiol for the ERTooltip estrogen receptor, dexamethasone for the GRTooltip glucocorticoid receptor, aldosterone for the MRTooltip mineralocorticoid receptor, dihydrotestosterone for SHBGTooltip sex hormone-binding globulin, and cortisol for CBGTooltip corticosteroid-binding globulin. Sources: See template. |
See also
[edit]References
[edit]- ^ Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 660–. ISBN 978-1-4757-2085-3.
- ^ Mozayani A, Raymon L (15 October 2003). Handbook of Drug Interactions: A Clinical and Forensic Guide. Springer Science & Business Media. pp. 501–. ISBN 978-1-59259-654-6.
- ^ Challener CA (1 December 2001). Chiral Drugs. Wiley. p. 131. ISBN 978-0-566-08411-9.
- ^ Buchborn E, Jahrmärker H, Karl HJ, Martini GA, Müller W, Riecker G, Schwiegk H, Siegenthaler W, Stich W (2 July 2013). Therapie innerer Krankheiten. Springer-Verlag. pp. 409–. ISBN 978-3-662-10489-7.
- ^ Svenska läkartidningen. Sveriges Läkarförbund. 1961. p. 1961.
Progestogens (and progestins) |
| ||||
---|---|---|---|---|---|
Antiprogestogens |
| ||||
|
ARTooltip Androgen receptor |
| ||||||
---|---|---|---|---|---|---|---|
GPRC6A |
| ||||||
PRTooltip Progesterone receptor |
| ||||||
---|---|---|---|---|---|---|---|
mPRTooltip Membrane progesterone receptor (PAQRTooltip Progestin and adipoQ receptor) |
| ||||||
This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it. |
This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |